Composite valuation range · conservative $22–$24 / fair $29–$39 / optimistic $53–$58. At $19.27, Below conservative intrinsic value · deep margin of safety.
At publication $29.91 (Jul 3, 2026)
WSJ reported Legend shares rose more than 40% after early LB2501 data showed tumor shrinkage in a small lymphoma study.
Possible impact:May influence near-term sentiment and sharpen investor focus on the commercial potential of next-generation CAR-T.
Legend reported early LB2501 Phase 1 data in relapsed/refractory NHL, with all six high-dose patients responding and five complete responses.
Possible impact:May affect expectations for Legend's in vivo CAR-T platform value, pipeline probability of success, and potential M&A premium.
WSJ discussed J&J's oncology deal strategy, highlighting Legend as its Carvykti partner and a focus of in vivo CAR-T acquisition speculation.
Possible impact:May affect expectations for strategic deal potential, partnership dynamics, and valuation premium.
Johnson & Johnson's first-quarter report showed Carvykti sales about 3% above expectations, alongside oncology strength.
Possible impact:May affect expectations for Carvykti uptake, Legend's collaboration revenue, and its path toward profitability.
J&J reportedly exited several biotech holdings but retained 814,586 Legend Biotech shares in an updated holdings disclosure.
Possible impact:May affect expectations around J&J partnership stability and potential strategic transaction optionality.
Automatically summarized from public sources; for context only, not investment advice.
Data from EODHD, shown in the reporting currency; for reference only, not investment advice.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Coming soonThis section is being filled in — check back soon.
Coming soonThis section is being filled in — check back soon.
